CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2008-03-21): EU follows U.S. with Tysabri liver warning


EU follows U.S. with Tysabri liver warning

Last Updated: 2008-03-21 9:45:13 -0400 (Reuters Health)

LONDON (Reuters) - The European Medicines Agency said on Thursday that warnings about liver injury should be added to the product information for Biogen Idec Inc and Elan Corp Plc's multiple sclerosis drug Tysabri.

The move follows a similar move by the U.S. Food and Drug Administration earlier this year.

The European watchdog said doctors should monitor the liver function of patients receiving Tysabri and patients who observe any signs of liver injury should see their doctor.

Tysabri has been haunted by safety concerns since it was approved.

Sales of the drug were suspended in 2005 amid three cases of progressive multifocal leukoencephalopathy, or PML. The drug returned to the market in 2006 with limits after the FDA decided that MS patients were willing to accept the risks in light of possible benefits.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.